246362 FDA: A Scorecard on the Agency's Steps Towards Greater Transparency and Accountability

Monday, October 31, 2011

Francesca Grifo, PhD , Scientific Integrity Program, Union of Concerned Scientists, Washington, DC
Art Levin, MPH , Director, Center For Medical Consumers, New York, NY
Diana M. Zuckerman, PhD , 1701 K Street, N.W., National Research Center for Women & Families, Washington, DC

Learning Areas:
Advocacy for health and health education

Learning Objectives:
1) Describe the the Food and Drug Administration Amendments Act, and whether they have effected more accountability and transparency at the agency. 2) Identify the current political landscape and budget realities and their impacts on FDA’s reform initiatives. 3)Assess the FDA Commissioner Margaret Hamburg's conflict of interest guidance and its impact on reducing special interest influence at the agency.

Keywords: FDA, Accountability

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have planned panel presentations at previous conferences.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: Medical Care Poster Session #4: Improving care in drugs and delivery
See more of: Medical Care